A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Natalizumab (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Acronyms OPUS
- Sponsors Biogen
- 17 Sep 2018 Planned primary completion date changed from 17 Jul 2019 to 18 Jul 2019.
- 01 Aug 2018 Planned End Date changed from 22 Apr 2022 to 17 Jul 2020.
- 24 Oct 2017 Status changed from not yet recruiting to recruiting in Oct 2017, according to a Biogen media release.